Marker Therapeutics, Inc. Banner Image

Marker Therapeutics, Inc. has reached its limit for free report views

Work for Marker Therapeutics, Inc.? Upgrade Your Profile and unlock all your annual reports.

Marker Therapeutics, Inc.

  • Ticker MRKR
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
Marker Therapeutics, Inc. Logo Image
  • 11-50 Employees
  • Based in Houston, Texas
Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Marker’s cell therapy technology is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor associated antigens (i.e. tumorMore targets) and kill tumor cells expressing those targets. This population of T cells is designed to attack multiple tumor targets following infusion into patients and to activate the patient’s immune system to produce broad spectrum anti-tumor activity. Because Marker does not genetically engineer its T cell therapies, they believe that their product candidates will be easier and less expensive to manufacture, with reduced toxicities, compared to current engineered CAR-T and TCR-based approaches, and may provide patients with meaningful clinical benefit. As a result, Marker believes its portfolio of T cell therapies has a compelling product profile, as compared to current gene-modified CAR-T and TCR-based therapies.
Marker Therapeutics, Inc.

Most Recent Annual Report

Marker Therapeutics, Inc. MOST RECENT 2019 Annual Report and Form 10K

Report Locked. Marker Therapeutics, Inc. has reached its limit for free report views.

Older/Archived Annual Reports